These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Change in vascular adhesion protein-1 and metabolic phenotypes after vertical banded gastroplasty for morbid obesity.
    Author: Li HY, Lee WJ, Chen MJ, Chuang LM.
    Journal: Obes Res; 2005 May; 13(5):855-61. PubMed ID: 15919838.
    Abstract:
    OBJECTIVE: The association between circulating vascular adhesion protein-1 (VAP-1) and metabolic phenotypes has been shown to be inconsistent. The current study explored whether the changes in serum VAP-1 levels correlate with the changes in metabolic phenotypes after weight reduction surgery. RESEARCH METHODS AND PROCEDURES: Clinical characteristics and serum VAP-1 levels in 20 morbidly obese subjects (mean BMI 38.84 kg/m(2)) were measured before and after vertical banded gastroplasty. RESULTS: Before surgery, serum VAP-1 levels correlated positively with fasting plasma glucose (gamma = 0.56, p = 0.01) and negatively with insulin levels (gamma = -0.51, p = 0.021). After surgery, the changes in serum VAP-1 levels were negatively correlated with the changes in waist circumference (gamma = -0.57, p = 0.011), diastolic blood pressure (DBP) (gamma = -0.56, p = 0.015), and mean arterial pressure (gamma = -0.46, p = 0.055). In multivariate regression, serum VAP-1 levels were negatively correlated with waist circumference (beta = -2.36, p = 0.014) and DBP (beta = -3.02, p = 0.017) after adjusting for age and gender. The change in DBP was negatively correlated with the change in VAP-1 levels after adjusting for age, gender, and steady-state plasma glucose. DISCUSSION: The results suggest that VAP-1 levels are correlated with fasting glucose and insulin levels in morbidly obese subjects. After surgery, the changes in VAP-1 levels were associated with changes in visceral adiposity and DBP. Serum VAP-1 might modulate DBP independently from the changes in insulin resistance in morbidly obese people.
    [Abstract] [Full Text] [Related] [New Search]